查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
憩室炎疾病市場份額,規模,趨勢,行業分析報告,按類型,按療法,按最終用戶,按地區,按細分市場,預測，2023-2032 年
市場調查報告書
商品編碼
1287681

憩室炎疾病市場份額,規模,趨勢,行業分析報告,按類型,按療法,按最終用戶,按地區,按細分市場,預測，2023-2032 年

Diverticulitis Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Uncomplicated, Complicated); By Treatment; By End-User; By Region; Segment Forecast, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris 市場研究的一項新研究，到 2032 年，全球憩室炎疾病市場預計將達到 38.6 億美元。 該報告深入探討了當前市場動態，並對未來市場增長進行了分析。

老年人口的增長將導致患者數量的增加並擴大憩室病的市場。 因此，預計全球市場將需要用於改善治療的藥物。 對最先進醫療保健的需求不斷增長,吸煙率上升以及年輕人向久坐生活方式的轉變是主要驅動力。 例如，根據CDC 2022年報告，西弗吉尼亞州的吸煙率高達23.8%，為美國最高。 吸煙是可預防疾病的主要原因，僅在美國就造成大量死亡，吸煙每年導致近 500,000 480,000 人死亡。 但CDC預測，到2020年，將有3080萬美國人，即12.5%的成年人吸煙。

大腸憩室病或憩室病在世界範圍內變得越來越常見。 儘管大多數患者在很長一段時間內沒有症狀，但大腸憩室病，特別是急性憩室炎，相當常見，並開始給國家醫療保健系統帶來重大的經濟負擔。 例如，根據亞歷山大霍金斯 (Alexander T. Hawkins) 在 2022 年發表的一篇研究論文，60 歲以上的人中約有 33% 患有乙狀結腸憩室病，據說在發達國家更為常見。 多達 15% 的患者可能在一生中的某個階段患上憩室炎。

目前，重點是測試多種治療方式並確定最佳治療策略。 然而不幸的是，仍然缺乏可靠的數據來支持藥物治療預防急性憩室炎復發的功效。 在這裡，我們簡要描述這些治療的療效和未來前景。

憩室炎市場報告亮點

  • 2022年，“無並發症”將主宰市場，主宰市場。 市場擴大的主要原因是抗生素治療研究的不斷進步。
  • 到 2022 年，藥物療法將主導市場。 該類別受益於使用抗生素治療急性憩室炎引起的感染，這是市場增長的關鍵驅動力。
  • 到 2022 年，醫院將佔據市場中最大的收入部分。 市場增長的關鍵驅動力是醫院中有專家可以指導患者選擇合適的測試。
  • 到 2022 年，北美將佔全球收入的大部分。 在預測期內，預計市場將受益於老年人口不斷增長和人們對當地健康問題意識不斷增強等因素。
  • 在全球開展業務的公司包括 Sucampo Pharmaceuticals,Valeant Pharmaceuticals International,Synergy Pharmaceuticals,Ardelyx,Astellas Pharma,Novartis AG,Hikma Pharmaceuticals 和 Baxter International。

內容

第一章簡介

第 2 章執行摘要

第三章研究方法

第 4 章全球憩室炎疾病市場洞察

  • 憩室炎疾病市場 - 最終用戶概況
  • 憩室炎疾病市場動態
    • 驅動因素和機遇
      • 對久坐生活方式的適應能力增強，胃腸道顯著生長
      • 口服藥物的需求不斷增長
    • 制約因素和問題
      • 成本高
  • PESTEL 分析
  • 憩室炎疾病市場的最終用戶趨勢
  • 價值鏈分析
  • COVID-19 的影響分析

第 5 章全球憩室炎疾病市場（按類型）

  • 主要發現
  • 簡介
  • 並不復雜
  • 複雜

第 6 章全球憩室炎疾病市場（按治療）

  • 主要發現
  • 簡介
  • 醫學
  • 手術
  • 支持性護理
  • 青黴素類抗生素
  • 抗生素
  • 膳食補充劑
  • 點滴輸液

第 7 章全球憩室炎疾病市場（按最終用戶）

  • 主要發現
  • 簡介
  • 專業中心
  • 醫院
  • 研究中心

第 8 章全球憩室炎疾病市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年憩室炎疾病市場評估（按地區）
  • 憩室炎疾病市場 - 北美
    • 北美：2019-2032 年憩室炎疾病市場（按類型）
    • 北美：憩室炎疾病市場，按最終用戶劃分，2019-2032 年
    • 北美：憩室炎疾病市場（按治療方法），2019-2032 年
    • 憩室炎疾病市場 - 美國
    • 憩室炎疾病市場 - 加拿大
  • 憩室炎疾病市場 - 歐洲
    • 歐洲：2019-2032 年憩室炎疾病市場（按類型）
    • 歐洲：憩室炎疾病市場（按最終用戶），2019-2032 年
    • 歐洲：2019-2032 年憩室炎治療市場
    • 憩室炎疾病市場 - 英國
    • 憩室炎疾病市場 - 法國
    • 憩室炎疾病市場 - 德國
    • 憩室炎疾病市場 - 意大利
    • 憩室炎疾病市場 - 西班牙
    • 憩室炎疾病市場 - 荷蘭
    • 憩室炎疾病市場 - 俄羅斯
  • 憩室炎疾病市場 - 亞太地區
    • 亞太地區：2019-2032 年憩室炎疾病市場（按類型）
    • 亞太地區：憩室炎疾病市場（按最終用戶），2019-2032 年
    • 亞太地區：憩室炎疾病市場（按治療方法），2019-2032 年
    • 憩室炎疾病市場 - 中國
    • 憩室炎疾病市場 - 印度
    • 憩室炎疾病市場 - 馬來西亞
    • 憩室炎疾病市場 - 日本
    • 憩室炎疾病市場 - 印度尼西亞
    • 憩室炎疾病市場 - 韓國
  • 憩室炎疾病市場 - 中東和非洲
    • 中東和非洲：2019-2032 年憩室炎疾病市場（按類型）
    • 中東和非洲：2019-2032 年最終用戶憩室炎疾病市場
    • 中東和非洲：2019-2032 年憩室炎疾病治療市場
    • 憩室炎疾病市場 - 沙特阿拉伯
    • 憩室炎疾病市場 - 阿聯酋
    • 憩室炎疾病市場 - 以色列
    • 憩室炎疾病市場 - 南非
  • 憩室炎疾病市場 - 拉丁美洲
    • 拉丁美洲：2019-2032 年憩室炎疾病市場（按類型）
    • 拉丁美洲：憩室炎疾病市場，按最終用戶劃分，2019-2032 年
    • 拉丁美洲：憩室炎疾病市場（按治療方法），2019-2032 年
    • 憩室炎疾病市場 - 墨西哥
    • 憩室炎疾病市場 - 巴西
    • 憩室炎疾病市場 - 阿根廷

第 9 章競爭格局

  • 擴張和收購分析
    • 擴展名
    • 收購
  • 夥伴關係/協作/協議/披露

第 10 章公司簡介

  • Pfizer
  • G.D. Searle
  • Teva Pharmaceutical
  • Abbott Laboratories
  • Braun Medical
  • GSK
  • Bayer HealthCare
  • Roche Holding
  • Johnson and Johnson
  • Sucampo Pharmaceuticals
  • Valeant Pharmaceuticals
  • Synergy Pharmaceuticals
  • Ardelyx
  • Astellas Pharma
  • Novartis
  • Hikma Pharmaceuticals
  • Baxter International
Product Code: PM3168

The global diverticulitis disease market size is expected to reach USD 3.86 billion by 2032, according to a new study by Polaris market research. The report "Diverticular Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Uncomplicated, Complicated); By Treatment; By End-User; By Region; Segment Forecast, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rise in the elderly population causes a rise in the patient population, which in turn increases the market for diverticular illness. The worldwide market has therefore forecast the demand for medications for improved treatment. It has been primarily fueled by the rising demand for cutting-edge medical care, the rise in cigarette smoking, and the broad movement of young people toward sedentary lifestyles. For instance, West Virginia had the highest smoking rate in the United States in 2022, with a rate of 23.8%, according to the CDC's 2022 report. The leading cause of the preventable disease & recorded substantial deaths in the U.S alone, smoking accounts for almost 500,000 480,000 deaths annually. However, the CDC predicted that 30.8 million Americans or 12.5% of adults smoked cigarettes in 2020.

Diverticulosis and diverticular disease of the colon are becoming more common worldwide. Despite the fact that the majority of patients stay asymptomatic for a very long time, diverticular illness of the colon, particularly acute diverticulitis, is quite common and is beginning to put a large financial strain on national health systems. For instance, a research paper by Alexander T. Hawkins, published in 2022, states that diverticulosis of the sigmoid colon affects about 33% of people over the age of 60 and is frequent in the industrialized world. Diverticulitis could occur in up to 15% of these patients at some time in their lives.

The current emphasis is on determining the best therapy strategy through the testing of numerous treatments. Unfortunately, there is still a lack of solid data supporting the efficacy of a medicinal approach to preventing a recurrence of acute diverticulitis. Here, we give a succinct overview of these treatments' efficacy and prospects for the future.

Diverticular Disease Market Report Highlights

  • Uncomplicated will dominate the market in 2022, accounting for major sales. The primary reason for the market's expansion is the ongoing advancement in antibiotic treatment research.
  • In 2022, medications will rule the market. Since the primary element driving market growth is the use of antibiotics to treat infections that may arise in acute diverticulitis, the category benefits from this.
  • In 2022, hospitals made up the greatest revenue portion of the market. The key driver of market growth is the presence of experts in hospitals who can guide patients in selecting appropriate tests.
  • North America will produce majority of global income in 2022. Over the course of the forecast period, the market is predicted to gain from elements including the growing senior population and expanding public awareness of local health issues.
  • The global players with global presence include Sucampo Pharmaceuticals, Valeant Pharmaceuticals International, Synergy Pharmaceuticals, Ardelyx, Astellas Pharma, Novartis AG, Hikma Pharmaceuticals and Baxter International.

Polaris Market Research has segmented the Diverticular Disease Market report based on type, treatment, end-user and region:

Diverticular Disease, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Uncomplicated
  • Complicated

Diverticular Disease, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Medications
  • Surgery
  • Supportive care
  • Penicillin Antibiotic
  • Antibiotics
  • Dietary Supplements
  • IV fluids

Diverticular Disease, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Specialty centers
  • Hospitals
  • Research centers

Diverticular Disease, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Diverticulitis Disease Market Insights

  • 4.1. Diverticulitis Disease Market - End-User Snapshot
  • 4.2. Diverticulitis Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased sedentary lifestyle adaptation and significant gastrointestinal growth
      • 4.2.1.2. Rising Demand for Oral Drugs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Diverticulitis Disease Market End-User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Diverticulitis Disease Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Uncomplicated
    • 5.3.1. Global Diverticulitis Disease Market, by Uncomplicated, by Region, 2019-2032 (USD Billion)
  • 5.4. Complicated
    • 5.4.1. Global Diverticulitis Disease Market, by Complicated, by Region, 2019-2032 (USD Billion)

6. Global Diverticulitis Disease Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 6.3. Medications
    • 6.3.1. Global Diverticulitis Disease Market, by Medications, by Region, 2019-2032 (USD Billion)
  • 6.4. Surgery
    • 6.4.1. Global Diverticulitis Disease Market, by Surgery, by Region, 2019-2032 (USD Billion)
  • 6.5. Supportive care
    • 6.5.1. Global Diverticulitis Disease Market, by Supportive care, by Region, 2019-2032 (USD Billion)
  • 6.6. Penicillin Antibiotic
    • 6.6.1. Global Diverticulitis Disease Market, by Penicillin Antibiotic, by Region, 2019-2032 (USD Billion)
  • 6.7. Antibiotics
    • 6.7.1. Global Diverticulitis Disease Market, by Antibiotics, by Region, 2019-2032 (USD Billion)
  • 6.8. Dietary Supplements
    • 6.8.1. Global Diverticulitis Disease Market, by Dietary Supplements, by Region, 2019-2032 (USD Billion)
  • 6.9. IV fluids
    • 6.9.1. Global Diverticulitis Disease Market, by IV fluids, by Region, 2019-2032 (USD Billion)

7. Global Diverticulitis Disease Market, by End-User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • 7.3. Specialty centres
    • 7.3.1. Global Diverticulitis Disease Market, by Specialty centres, By Region, 2019-2032 (USD Billion)
  • 7.4. Hospitals
    • 7.4.1. Global Diverticulitis Disease Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.5. Research centres
    • 7.5.1. Global Diverticulitis Disease Market, by Research centres, By Region, 2019-2032 (USD Billion)

8. Global Diverticulitis Disease Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Diverticulitis Disease Market - North America
    • 8.3.1. North America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.3.3. North America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.4. Diverticulitis Disease Market - U.S.
      • 8.3.4.1. U.S.: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.5. Diverticulitis Disease Market - Canada
      • 8.3.5.1. Canada: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.4. Diverticulitis Disease Market - Europe
    • 8.4.1. Europe: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.4. Diverticulitis Disease Market - UK
      • 8.4.4.1. UK: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.5. Diverticulitis Disease Market - France
      • 8.4.5.1. France: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.6. Diverticulitis Disease Market - Germany
      • 8.4.6.1. Germany: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.7. Diverticulitis Disease Market - Italy
      • 8.4.7.1. Italy: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.8. Diverticulitis Disease Market - Spain
      • 8.4.8.1. Spain: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.9. Diverticulitis Disease Market - Netherlands
      • 8.4.9.1. Netherlands: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.10. Diverticulitis Disease Market - Russia
      • 8.4.10.1. Russia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.5. Diverticulitis Disease Market - Asia Pacific
    • 8.5.1. Asia Pacific: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.4. Diverticulitis Disease Market - China
      • 8.5.4.1. China: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.5. Diverticulitis Disease Market - India
      • 8.5.5.1. India: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.6. Diverticulitis Disease Market - Malaysia
      • 8.5.6.1. Malaysia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.7. Diverticulitis Disease Market - Japan
      • 8.5.7.1. Japan: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.8. Diverticulitis Disease Market - Indonesia
      • 8.5.8.1. Indonesia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.9. Diverticulitis Disease Market - South Korea
      • 8.5.9.1. South Korea: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.6. Diverticulitis Disease Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.4. Diverticulitis Disease Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.5. Diverticulitis Disease Market - UAE
      • 8.6.5.1. UAE: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.6. Diverticulitis Disease Market - Israel
      • 8.6.6.1. Israel: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.7. Diverticulitis Disease Market - South Africa
      • 8.6.7.1. South Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.7. Diverticulitis Disease Market - Latin America
    • 8.7.1. Latin America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.4. Diverticulitis Disease Market - Mexico
      • 8.7.4.1. Mexico: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.5. Diverticulitis Disease Market - Brazil
      • 8.7.5.1. Brazil: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.6. Diverticulitis Disease Market - Argentina
      • 8.7.6.1. Argentina: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Pfizer
    • 10.1.1. Company Overview
    • 10.1.2. Financial PerTreatmentance
    • 10.1.3. Treatment Benchmarking
    • 10.1.4. Recent Development
  • 10.2. G.D. Searle
    • 10.2.1. Company Overview
    • 10.2.2. Financial PerTreatmentance
    • 10.2.3. Treatment Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Teva Pharmaceutical
    • 10.3.1. Company Overview
    • 10.3.2. Financial PerTreatmentance
    • 10.3.3. Treatment Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Abbott Laboratories
    • 10.4.1. Company Overview
    • 10.4.2. Financial PerTreatmentance
    • 10.4.3. Treatment Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Braun Medical
    • 10.5.1. Company Overview
    • 10.5.2. Financial PerTreatmentance
    • 10.5.3. Treatment Benchmarking
    • 10.5.4. Recent Development
  • 10.6. GSK
    • 10.6.1. Company Overview
    • 10.6.2. Financial PerTreatmentance
    • 10.6.3. Treatment Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Bayer HealthCare
    • 10.7.1. Company Overview
    • 10.7.2. Financial PerTreatmentance
    • 10.7.3. Treatment Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Roche Holding
    • 10.8.1. Company Overview
    • 10.8.2. Financial PerTreatmentance
    • 10.8.3. Treatment Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Johnson and Johnson
    • 10.9.1. Company Overview
    • 10.9.2. Financial PerTreatmentance
    • 10.9.3. Treatment Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sucampo Pharmaceuticals
    • 10.10.1. Company Overview
    • 10.10.2. Financial PerTreatmentance
    • 10.10.3. Treatment Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Valeant Pharmaceuticals
    • 10.11.1. Company Overview
    • 10.11.2. Financial PerTreatmentance
    • 10.11.3. Treatment Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Synergy Pharmaceuticals
    • 10.12.1. Company Overview
    • 10.12.2. Financial PerTreatmentance
    • 10.12.3. Treatment Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Ardelyx
    • 10.13.1. Company Overview
    • 10.13.2. Financial PerTreatmentance
    • 10.13.3. Treatment Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Astellas Pharma
    • 10.14.1. Company Overview
    • 10.14.2. Financial PerTreatmentance
    • 10.14.3. Treatment Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Novartis
    • 10.15.1. Company Overview
    • 10.15.2. Financial PerTreatmentance
    • 10.15.3. Treatment Benchmarking
    • 10.15.4. Recent Development
  • 10.16. Hikma Pharmaceuticals
    • 10.16.1. Company Overview
    • 10.16.2. Financial PerTreatmentance
    • 10.16.3. Treatment Benchmarking
    • 10.16.4. Recent Development
  • 10.17. Baxter International
    • 10.17.1. Company Overview
    • 10.17.2. Financial PerTreatmentance
    • 10.17.3. Treatment Benchmarking
    • 10.17.4. Recent Development

List of Tables

  • Table 1 Global Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 3 Global Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 4 Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 7 North America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 8 U.S.: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 10 U.S.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 11 Canada: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 Canada: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 14 Europe: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 16 Europe: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 17 UK: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 19 UK: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 20 France: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 22 France: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 23 Germany: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 26 Italy: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 28 Italy: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 29 Spain: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 31 Spain: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 35 Russia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Russia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 41 China: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 43 China: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 44 India: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 46 India: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 50 Japan: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 52 Japan: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 56 South Korea: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 58 South Korea: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 65 UAE: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 67 UAE: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 68 Israel: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 70 Israel: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 71 South Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 South Africa: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 74 Latin America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 76 Latin America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 77 Mexico: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 79 Mexico: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 80 Brazil: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 82 Brazil: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 83 Argentina: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Argentina: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Diverticulitis Disease Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Diverticulitis Disease Market, by Treatment, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Diverticulitis Disease Market, by Type, 2021 & 2030 (USD Billion)
  • Figure 10. Market by End-User
  • Figure 11. Global Diverticulitis Disease Market, by End-User, 2021 & 2030 (USD Billion)
  • Figure 12. Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Diverticulitis Disease Market